<DOC>
	<DOCNO>NCT02132390</DOCNO>
	<brief_summary>Compare potential benefit adjuvant toremifene without goserelin premenopausal woman stage I-IIIA , hormonal receptor positive breast cancer accompany without chemotherapy induce amenorrhoea .</brief_summary>
	<brief_title>Adjuvant Toremifene With Without Goserrelin Premenopausal Women With Stage I-IIIA , Hormonal Receptor Positive Breast Cancer Accompanied With Without Chemotherapy Induced Amenorrhoea</brief_title>
	<detailed_description>This single center , randomize , control study . Patients undergo surgical resection standard Doxorubicin/Cyclophosphamide Followed Docetaxel ( AC-T ) . Chemotherapy begin within 4 week surgery patient randomize arm I-IV . Arm I : patient n't CIA receive oral toremifene daily . Treatment continue 5 year absence disease progression unacceptable toxicity . Arm II : patient CIA receive toremifene arm I . Arm III : patient without CIA receive oral toremifene goserelin ovarian function suppression . Arm IV : patient CIA receive oral toremifene goserelin ovarian function suppression . Patients follow every 6 month 5 year annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>Written informed consent must obtain document accord local regulatory requirement prior begin specific protocol procedure Age least 18 45 year Spontaneous regular menstrual period study entry FSH 15 mlU/ml follicular phase Histologically confirm primary breast cancer need anthracyclinebased chemotherapy Steroid receptor ( estrogen progesterone ) positive tumor ( diagnosis accord hospital standardprocedures ) No clinical evidence local recurrence distant metastasis . Complete stag workup within 3 month prior registration . All patient must ( bilateral ) mammography breast MRI , chest Xray ; test may perform clinically indicated KarnofskyIndex &gt; 80 % Life expectancy least 10 year , disregard diagnosis cancer Adequate organ function include normal red white blood count , platelet , serum creatinine , bilirubin , transaminase within normal range institution Patients underwent standard Doxorubicin/Cyclophosphamide Followed Docetaxel ( ACT ) Patients must available compliant treatment followup . Patients register trial must treat follow participate center . Known hypersensitivity reaction investigational compound incorporated substance Prior cytotoxic treatment reason Suspected ( primary secondary ) ovarian insufficiency Pregnant lactating patient . Patients childbearing potential must negative pregnancy test ( urine serum ) within 14 day prior registration must implement adequate nonhormonal contraceptive measure study treatment ; prior use hormonal contraceptive discontinue first Goserelin injection Other serious illness medical condition may interfere understand give informed consent conduct study Prior concomitant secondary malignancy ( except nonmelanomatous skin cancer carcinoma situ uterine cervix ) Concurrent treatment experimental drug anticancer therapy Concurrent treatment sex hormone . Prior treatment must stop study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Chemotherapy induce amenorrhea</keyword>
	<keyword>Goserelin</keyword>
</DOC>